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Abstract
Purpose We have developed a sequencing assay for
determining the usage of the genotypic HIV-1 co-receptor
using peripheral blood mononuclear cell (PBMC) DNA in
virologically suppressed HIV-1 infected patients. Our
specific aims were to (1) evaluate the efficiency of V3
sequences in B versus non-B subtypes, (2) compare the
efficiency of V3 sequences and tropism prediction using
whole blood and PBMCs for DNA extraction, (3) compare
the efficiency of V3 sequences and tropism prediction
using a single versus a triplicate round of amplification.
Results The overall rate of successful V3 sequences
ranged from 100 % in samples with [3,000 copies HIV-1
DNA/106 PBMCs to 60 % in samples with \100 copies
total HIV-1 DNA /106 PBMCs. Analysis of 143 paired
PBMCs and whole-blood samples showed successful V3
sequences rates of 77.6 % for PBMCs and 83.9 % for
whole blood. These rates are in agreement with the tropism
prediction obtained using the geno2pheno co-receptor
algorithm, namely, 92.1 % with a false-positive rate (FPR)
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of 10 or 20 % and of 96.5 % with an FPR of 5.75 %. The
agreement between tropism prediction values using single
versus triplicate amplification was 98.2 % (56/57) of
patients using an FPR of 20 % and 92.9 % (53/57) using an
FPR of 10 or 5.75 %. For 63.0 % (36/57) of patients, the
FPR obtained via the single amplification procedure was
superimposable to all three FPRs obtained by triplicate
amplification.
Conclusions Our results show the feasibility and consis-
tency of genotypic testing on HIV-1 DNA tropism, sup-
porting its possible use for selecting patients with
suppressed plasma HIV-1 RNA as candidates for CCR5-
antagonist treatment. The high agreement between tropism
prediction by single and triple amplification does not sup-
port the use of triplicate amplification in clinical practice.
Keywords HIV DNA  Tropism  Virologically
suppressed patients  CCR5 antagonists  Geno2pheno
Introduction
Human immunodeficiency virus-1 (HIV-1) enters the target
cell using CD4 molecules as primary receptors and either
one of two chemokine receptors, CCR5 or CXCR4. On the
basis of co-receptor usage, HIV-1 strains are classified as
CCR5-, CXCR4- or dual/mixed tropic. The introduction
into clinical practice of the CCR5 antagonist maraviroc has
required the testing of HIV tropism in each patient prior to
therapy [1].
Among the different approaches for tropism determi-
nation, genotypic population sequencing predicts HIV
co-receptor usage based on the sequence of the V3 loop of
HIV-1 gp120. This test has been shown to be a valuable
tool in clinical routine and has been incorporated into
several guidelines to predict viral tropism [1, 2]. To date,
the performances of various genotypic tropism tests have
been evaluated in RNA samples from viremic patients [3–
7]. Less information is available on the efficiency of V3
sequencing of HIV-DNA from patients with suppressed
viremia. Assessing this efficiency has important clinical
implications since it would allow maraviroc to be consid-
ered part of the switch or simplification strategies in drug-
treated patients with undetectable plasma HIV-1 RNA. In
addition, as shown in maraviroc clinical trials, a potential
immune benefit of this drug might encourage its use as part
of intensification strategies in HIV-1-infected patients with
impaired CD4 gains despite prolonged suppression of HIV
replication with antiretroviral therapy (ART) [8].
Given this background and within the framework of the
DIVA (DNA Tropism Italian Validation Concerted Action)
group (Appendix 1), we have developed a genotypic tro-
pism test on HIV-DNA for routine clinical diagnostic
laboratory testing. In an earlier study, this test was sub-
jected to an inter-laboratory validation procedure [9]. Here,
our specific aims are to (1) evaluate the efficiency of V3
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sequencing in B versus non-B subtypes, (2) compare the
efficiency of V3 sequencing and tropism prediction using
whole blood and peripheral blood mononuclear cells
(PBMCs) for DNA extraction, and (3) compare the effi-
ciency of V3 sequencing and tropism prediction using a
single versus a triplicate round of amplification.
Materials and methods
Patients
Contemporary plasma and whole-blood samples were
collected from 253 HIV-1 infected highly active ART
(HAART)-treated patients with plasma HIV-1 RNA of\50
copies/ml who were followed in 18 centers participating in
the DIVA study group. All patients were naı¨ve to
maraviroc.
Viral amplification and sequencing
HIV-1 DNA was extracted from whole blood or PBMCs
using the QIAamp DNA Blood Mini kit and QIAamp DNA
Mini kit, respectively, according to the manufacturer’s
instructions (Qiagen, Hilden, Germany). PBMCs were
obtained by separation through a Ficoll-Hypaque gradient
as previously described [10].
Amplification of the V3-containing region of the env
gene consisted of two amplification steps using primers
designed on the basis of the gp120 consensus B sequence
(downloaded from Los Alamos HIV Database: http://www.
hiv.lanl.gov/cgi-bin/NEWALIGN/align.cgi). The forward
primer ENVS10 [50-CCAATTCCCATACATTATTGT-30;
nucleotide (nt) 538–558 of the HIV-1 gp120 env gene] and
the reverse primer V3AS5 (50-CTTCTCCAATTGTCCCT
CA-30; nt 1,292–1,310) were used for the first amplification
step, while the inner forward primer V3S2 (50-CAG-
CACAGTACAATGTACACA-30; nt 630–650) and V3AS5
were used for the second one. The length of the amplicon
produced, including the V3 sequence, is 660 nt.
The conditions for the first amplification were one
cycle at 93 C for 12 min, 40 cycles at 93 C for 30 s,
50 C for 30 s, and 72 C for 50 s, with a final step at
72 C for 10 min. The total reaction volume (40 ll)
contained the following master mix: 5 ll of Taq buffer
109, 3 ll of 25 mM MgCl2, 28.95 ll of DNase- and
RNase-free bidistilled water, 0.75 ll of 10 lM primers,
0.8 ll of 12.5 mM dNTPs, 0.75 ll of Taq (5 U/ll). The
amplification conditions for the semi-nested PCR were
one cycle at 93 C for 12 min, 40 cycles at 93 C for 30 s,
51 C for 30 s, and 72 C for 50 s, with a final step at
72 C for 10 min. The total reaction volume (45 ll)
contained the following master mix: 5 ll of Taq Gold PE
buffer 109, 3 ll of 25 mM MgCl2, 33.95 ll of DNase-
and RNase-free bi-distilled water, 0.75 ll of 10 lM
primers, 0.8 ll of 12.5 mM dNTPs, 0.75 ll of Taq
(5 U/ll).
The PCR product was purified using the Microcon PCR
purification kit (Millipore Corp., Billerica, MA). Negative
and positive control samples were included in each PCR
run to exclude false-positive and false-negative reactions.
PCR products were then sequenced using the BigDye
Terminator v.3.1 Cycle Sequencing kit (Applied Biosys-
tems, Foster City, CA) and an automated sequencer (ABI-
3,100; Applied Biosystems). Four different overlapping
sequence-specific primers were used to ensure coverage of
the V3-sequence by at least two sequence segments. The
sequencing conditions were one cycle at 96 C for 3 min,
25 cycles at 96 C for 30 s, 50 C for 10 s, and 60 C for
4 min), and the following primers were used: V3S6 (50-CT
GTTAAATGGCAGTCTAGC-30), V3S5 (50-GTTAAATG
GCAGTCTAGCAG-30), V3AS1 (50-GAAAAATTCCCCT
CCACAATT-30), and V3AS3bis (50-CAATTTCTGGGTC
CCCTC-30).
The Siemens sequencing kit was used in three of the
centers participating in the DIVA project. In particular,
CLIP sequencing was performed using the Trugene Core kit
according to the manufacturer’s instructions. The four CLIP
reaction mixture contained 2.8 ll of CLIP buffer, 8.8 ll of
molecular water, 2.8 ll of forward primer V3S6 (50-Cy5.5-
CTGTTAAATGGCAGTCTAGC-30) and reverse primer
V3AS3bis (50-Cy5-50CAATTTCTGGGTCCCCTC GGT-
30) (3 lM), 5 ll of sample cDNA, 3 ll of the four termi-
nator nucleotides, and 4.4 ll of Thermo Sequenase (GE
Healthcare Life Sciences, UK) enzyme diluted 1:10 (32 U/
ll). The CLIP cycling profile was 5 min at 94 C, followed
by 30 cycles of 20 s at 94 C, 20 s at 55.5 C, and 60 s at
70 C, with a final extension of 7 min at 70 C and 30 min
at 4 C. Thereafter, Stop Loading Dye (6 ll) was added.
Samples were heated to 94 C for 3 min and incubated at
4 C. Fragments were separated on a TruGene Tower
(Siemens) with a 6 % polyacrylamide gel. Sequence data
were acquired and analyzed using the OpenGene DNA
Sequencing System (Siemens) and read against a V3 loop
sequence-specific reference.
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For each sample, HIV-1 subtype was determined by
phylogenetic analysis of the related pol nucleotide
sequences. Phylogenetic analysis of V3 sequences was also
used to identify potential cross-contaminations during the
process.
To compare tropism prediction via single or triplicate
amplification, DNA extracted from whole blood was divi-
ded into four aliquots. One aliquot was randomly chosen to
be processed by a single amplification. Each of the
remaining three aliquots underwent a process of V3
amplification and sequencing.
Genotypic prediction of viral tropism
HIV-1 co-receptor usage was inferred from the V3 nucle-
otide sequence by using the geno2pheno algorithm (http://
coreceptor.bioinf.mpi-inf.mpg.de/) and by using the clonal
version of geno2pheno set at a false-positive rate (FPR) of
20 %, as proposed by the current guidelines for tropism
determination [1], and 5.75 and 10 %.
For the triple amplification, an isolate was predicted as
CXCR4-tropic if at least one of the three tests reported it to
be CXCR4-tropic.
Quantification of total HIV-1 DNA
To quantify total HIV-1 DNA in PBMCs, we adapted the
Real Time TaqMan protocol published by Viard et al. [11]
the LightCycler system (Roche Molecular Biochemicals,
Indianapolis, IN). The methodology is describd in detail in
Appendix 2.
Results
Patient’s characteristics
This study included a total of 253 HIV-1 infected HAART-
treated patients with undetectable plasma HIV-1 RNA
(\50 copies/ml). The clinical and viro-immunological
characteristics of patients are shown in Table 1. Median
time of virological success was 3.5 [interquartile range
(IQR) 2.1–5.9] years. At the time of sample collection, the
median CD4 cell count was 578 (IQR 416–780) cells/ll.
HIV-1 subtyping
HIV-1 subtyping (available for 133 patients and assessed
by phylogenetic analysis based on HIV-1 pol sequences)
showed that the large majority of patients harbored HIV-1
B subtype (N = 100, 75.2 %). Other non-B subtypes were
CRF02_AG (N = 5, 3.8 %), C (N = 6, 4.5 %), and F
(N = 9, 6.8 %). For 122 patients, both the HIV-1 pol and
V3 sequences were available. HIV-1 subtyping by phylo-
genetic analysis using either the pol or env sequences was
concordant for 86.1 % (105/122) of patients. In 15 patients,
pol sequences based phylogenetic analysis predicted the
presence of recombinant forms (7/15) or subtype F1(5/15),
while V3 sequence-based phylogenetic analysis predicted
the presence of B subtypes. In the remaining three cases,
phylogenetic analysis based on pol and env sequences
predicted the presence of different non-B subtypes. Thus,
misclassifications were mainly due to the presence of non-
B subtypes or recombinant forms.
Efficiency of V3 sequencing and tropism prediction
A total of 201 V3 sequences were obtained among the 253
samples analyzed. In order to define the efficiency of V3
sequencing according to the level of total HIV-1 DNA, we
analyzed 178 samples for the level of total HIV-1 DNA
available. The success rate of V3 sequencing was 93.5 %
in samples with [100 copies total HIV-1 DNA/106
PBMCs, reaching 100 % in samples with [3,000 copies
total HIV-1 DNA/106 PBMCs. In samples with \100
copies total HIV-1 DNA/106 PBMCs, the success rate of
V3 sequencing was 60 % (Fig. 1a). Thus, this methodology
for V3 sequencing on proviral DNA performed well, also at
a low level of HIV-DNA. No differences in the success rate
of V3 sequencing were observed at the three centers using
the Siemens methodology.
Among the 33 patients infected with non-B subtypes, V3
sequences were obtained for 28 (84.8 %) patients. V3
sequences were also obtained for atypical recombinants
forms such as CFR31 and CRF06.
Tropism prediction
Among the 201 V3 sequences obtained, CXCR4 co-
receptor usage was reported in 35 (17.4 %), 48 (23.9 %),
and 68 (33.6 %) of patients using an FPR of 5.75, 10, and
20 %, respectively. A FPR of\5.75 % was associated with
a lower CD4 cell count at the time of V3 genotypic tropism
testing and with a lower increase in CD4 cell count from
the beginning of HAART therapy to the time of V3
sequencing [median (IQR) CD4 cell count: 459 (317–590)
for FPR of \5.75 % vs. 519 (360–862) for FPR of
5.75–20 % and 579 (435–755) for FPR of [20 %; median
(IQR) gain of CD4 cell count: 20 (-58 to 163) for FPR of
\5.75 % vs. 187 (60–281) for FPR of 5.75–20 % and 164
(22–379) for FPR of [20 %]. Interestingly, a lower FPR
were also associated with a higher CD8 cell count at the
time of V3 genotyping [median (IQR) CD8 cell count:
1,120 (711–1,464) for FPR of \5.75 % vss 760
(641–1,142) for FPR of 5.75-20 % and 745 (587–987) for
of FPR [20 %] (Table 2).
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Comparison of the efficiency of V3 sequencing
and tropism prediction using whole blood
versus PBMCs for DNA extraction
A total of 143 pairs of PBMCs and whole blood samples
obtained from identical collection tubes were processed.
The overall rate of successful V3 sequencing was 77.6 %
(111/143) and 83.9 % (120/143) for PBMCs and whole
blood aliquots, respectively (Fig. 1b). In particular, V3
sequences were obtained from both whole blood and
PBMCs in 67.8 % (97/143) of the samples. V3 sequences
were obtained from only PBMCs and only whole blood in
16.3 % (N = 23) and 9.8 % (N = 14) of samples,
respectively. For the remaining 6.3 % (N = 9) of samples,
V3 sequences were not obtained from either PBMCs or
whole blood. Samples not amplified and samples success-
fully amplified only from PBMCs were characterized by a
lower total HIV-DNA quantification.
The agreement with the prediction of viral tropism was
92.1 % when an FPR of 10 and 20 % was used. This
correspondence increased to 96.5 % with an FPR of
5.75 %. The median similarity between V3 sequences
obtained via whole blood and via PBMCs was 99.5 % (IQR
90.6–100). The distribution of FPRs obtained via whole
Table 1 Patients’ characteristics
Characteristics Overall samplesa
(N = 253)
Amplified samplesa
(N = 201)
Not amplified samplesa
(N = 52)
P value
Male, N (%) 148 (72.2) 123 (74.1) 25 (64.1) ns
Italians, N (%) 158 (91.9) 129 (93.5) 29 (85.3) ns
Risk factors, N (%)
Heterosexual 60 (42.9) 48 (42.1) 12 (46.1) ns
Homosexual 38 (27.1) 30 (26.3) 6 (23.1) ns
Drug addiction 42 (30) 36 (31.6) 8 (30.8) ns
Age, median (IQR) 49 (42–55) 48 (43–54) 46 (43–58) ns
Drug-experienced patients, N (%) 156 (94.0) 120 (97.6) 36 (83.7) 0.003
HIV-1 subtypes, N (%)b
B 100 (75.2) 78 (73.6) 22 (81.5) ns
CRF02_AG 5 (3.8) 5 (4.7) 0 (0.0) ns
C 6 (4.5) 6 (5.7) 0 (0.0) ns
F 9 (6.8) 7 (6.6) 2 (7.4) ns
Others 13 (9.8) 10 (9.4) 3 (11.1) ns
Year of starting current therapy, median (IQR) 2009 (2007–2010) 2009 (2007–2010) 2009 (2008–2010) ns
Virological suppression time (year), median (IQR) 3.5 (2.1–5.9) 3.2 (1.9–5.4) 2.9 (2.1–5.8) ns
Current therapy, N (%)
Non-nucleoside RT inhibitors 67 (34.3) 46 (31.5) 21 (42.8) ns
Protease inhibitors 86 (44.1) 70 (47.9) 16 (32.6) ns
Raltegravir 26 (13.3) 23 (15.7) 9 (18.4) ns
Unknown 16 (8.2) 7 (4.8) 3 (6.1) ns
Total HIV DNA copies/10e-6 PBMCs, median (IQR) 1,582 (279–5,574) 1,197 (325–2,354) 365 (13–1,812) ns
HIV RNA, log10, median (IQR)
Pre-HAART 4.9 (4.0–5.4) 5.0 (4.0–5.4) 4.9 (4.0–5.3) ns
At V3 sampling date \1.7 \1.7 \1.7 ns
CD4 cells/mm3, median (IQR)
Pre-HAART 250 (147–380) 261 (138–367) 300 (174–415) ns
Nadir 211 (110–300) 201 (115–301) 230 (79–335) ns
At V3 sampling date 578 (416–780) 368 (265–546) 558 (317–670) 0.03
Fisher exact test and Wilcoxon test were used for dichotomic and continuous variables, respectively
IQR Interquartile range, HAART highly active antiretroviral therapy, PBMCs peripheral blood mononuclear cells, ns not significant
a The table reports both the characteristics of the overall group of patients analyzed (N = 253) and stratified in patients with or without
successful V3 sequencing
b Human immunodeficiency virus-1 (HIV-1) subtypes and recombinant forms were available for 133 patients and were determined by phy-
logenetic analysis using HIV-a pol sequences
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blood and via PBMCs was superimposable, and for 47.4 %
(46/97) of patients, the V3 sequences obtained via whole
blood and PBMCs had the same FPR value.
Triplicate versus single amplification procedure
Of the 243 samples, 57 were processed by both single and
triplicate amplification of the V3 region. The concordance
between tropism prediction using the single versus the
triplicate amplification was 98.2 % (56/57) of samples/
patients using a FPR of 20 % and 92.9 % (53/57) using a
FPR of 5.75 or 10 %. For 63.1 % (36/57) of patients/
samples, the FPR value obtained via the single amplifica-
tion procedure was superimposable onto the FPRs obtained
by triplicate amplification (Fig. 2), thus indicating a sub-
stantial similarity among viral quasispecies. Among the
four discordant cases, three resulted in reclassification of
CCR5 in CXCR4 tropism. In these three samples, the
tropism prediction of the V3 sequences obtained by trip-
licate amplification always revealed the co-existence of
CCR5-using and CXCR4-using strains (Table 3). No
relationship was found between the discordant tropism
prediction and HIV-1 DNA content (Table 3).
Discussion
We have described the performance of a population-based
V3 sequencing method for tropism prediction on HIV-1
DNA. This assay was effective for HIV-1 tropism deter-
mination in patients with undetectable plasma HIV-1 RNA.
Indeed, the rate of successful V3 sequencing (using whole
blood for DNA extraction) was 93.5 % in samples with
[100 copies HIV-1 DNA /106 PBMCs, reaching 100 % in
samples with [300 copies HIV-1 DNA/106 PBMCs, a
A
B
Fig. 1 Rate of successful V3
sequencing. a Rate of
successful V3 sequencing based
on different levels of total HIV-
1 DNA quantification. b Rate
of successful V3 sequencing in
patients for which DNA was
extracted from whole blood
(WB) or peripheral blood
mononuclear cells (PBMCs).
The quantification of total HIV-
DNA is expressed in copies/106
cells
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percentage comparable to that observed for V3 sequencing
from HIV-RNA samples in viremic patients [6].
The method did not suffer from subtype-related vari-
ability within HIV group M subtypes. Indeed, 84.8 % of
samples from non-B subtypes were successfully amplified
and sequenced. In this study, HIV-1 subtyping was inferred
by phylogenetic analysis based on pol sequences. However,
we did note some misclassifications when phylogenetic
analysis based on env sequences and the geno2pheno
algorithm were used to infer HIV-1 subtypes.
In addition, in 15 of the 133 patients with CCR5 tro-
pism, maraviroc had been introduced into their antiretro-
viral regimen. All of these 15 patients had detectable
plasma HIV-1 RNA at week 12, and 12 of the 15 patients
had detectable HIV-1 RNA at week 24. All 15 patients
maintained a plasma HIV-1 RNA level of\50 copies/ml at
both week 12 and 24. Although further clinical evaluation
of genotypic tropism testing is needed, this result supports
the use of genotypic tropism testing in proviral DNA to
select patients as candidates for maraviroc treatment. This
is in line with a recent study showing that among 71
patients treated with maraviroc, a plasma HIV-1 RNA of
\50 copies/ml was maintained in 85.4 % of cases who had
a viral load quantification at month 9 [12].
In this study, CXCR4-using viruses were detected in
17.4, 23.9, and 33.6 % of patients using an FPR of 5.75, 10,
and 20 %, respectively. This prevalence is in line with the
results reported from two other independent studies in a
group of virologically suppressed patients [4, 13]. In these
studies, a subset of 78 and 140 HAART-treated patients
Table 2 Characteristics of R5 and X4 proviruses in patients from the DIVA project according to the false-positive rate
Characteristics Patients with FPR P value for trenda P value
\5.75 vs [5.75a
\5.75 % 5.75–20 % [20 %
Viremia at baseline log copies/ml 1.7 (0.7–4.8) 1.7 (1.6–4.5) 3.1 (1.6–4.4) ns ns
Pre-HAART Viremia 5.1 (4.0–5.3) 5.1 (4.3–5.3) 5.2 (4.2–5.4) ns ns
CD4 cells/ll at time of V3 sequencing 459 (317–590) 519 (360–862) 579 (435–755) 0.06 0.02
CD4 cells/ll at baseline (BL) 336 (249–630) 368 (228–592) 371 (239–498) ns ns
CD4 nadir cells/ll 153 (51–292) 216 (151–309) 203 (125–302) ns ns
Pre-HAART CD4 cell count cells/ll 257 (97–445) 219 (107–419) 263 (152–350) ns ns
Change in CD4 cells/ll
Between BL and V3 sequencing 20 (-58 to 163) 187 (60–281) 164 (22–379) 0.005 0.001
Between pre-HAART and V3 sequencing 212 (-37 to 301) 314 (206–622) 309 (182–552) 0.01 0.004
CD8 count at V3 sequencing 1,120 (711–1,464) 760 (641–1,142) 745 (587–987) 0.01 0.004
CD8 percentage at V3 sequencing 54 (47–63) 45 (35–55) 40 (34–46) 0.001 \0.001
Time under virological suppression (years) 3.0 (1.7–5.8) 3.9 (2.2–6.4) 3.6 (2.1–5.9) ns ns
Data are presented as the median with the interquartile range (IQR) given in parenthesis
FPR False-positive rate
a Statistically significant difference was calculated by the chi-square test for trend and by the Fisher exact test between patients with an FPR of
\5.75 % and those with an FPR of [5.75%
Fig. 2 Distribution per patient
of the false-positive rate (FPR)
obtained by single amplification
(black points) and the three
FPRs obtained by triplicate
amplification (grey points).
Only patients with an X4
provirus were included in the
graph
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with suppressed viremia were studied, with CXCR4-using
viruses detected in proviral DNA in 34.0 [4] and 30.0 %
[13] of patients analyzed, respectively.
This is the first study to evaluate the rate of successful
V3 sequencing and tropism prediction using PBMCs and
whole blood for DNA extraction. We found a comparable
rate of successful V3 sequencing and a high concordance
of tropism prediction with the most commonly used FPRs.
These results suggest that whole blood can be used in
clinical practice for determining HIV-1 DNA co-receptor
tropism, thereby eliminating the need and inconvenience of
PBMC preparation.
We also addressed the issue of single versus triplicate
amplification for tropism determination. A previous study,
conducted in 43 HIV-DNA samples from viremic patients,
showed that triplicate testing on HIV-1 DNA resulted in
the reclassification from CCR5 to CXCR4 tropism in one,
two, and four patients using a FPR of 5.75, 10, and 20 %,
respectively [14]. A similar reclassification rate was
observed in the Italian Cohort of Antiretroviral Naive
Patients cohort when triplicate testing was performed using
an FPR of 10 % on 42 paired HIV-DNA and -RNA sam-
ples from viremic patients [15]. In our group of 57 HIV-
DNA samples obtained from virologically suppressed
patients, we found a high agreement in tropism prediction
using the single versus the triplicate amplification (98.2 %
using a FPR of 20 % and 92.9 % using a FPR of 5.75 and
10 %), and for a large proportion of samples the FPR value
obtained via the single amplification procedure was
superimposable onto those obtained by triplicate amplifi-
cation. Triplicate amplification resulted in reclassification
from CCR5 to CXCR4 tropism for only three, three, and
one samples using a FPR of 5.75, 10 and 20 %, respec-
tively. Thus, the high concordance of tropism prediction
among samples processed via single and triple amplifica-
tion suggests that single amplification can be used in
diagnostic practice, as also suggested by the 2012 update of
the Austrian–German Treatment Guidelines (http://
coreceptor.bioinf.mpi-inf.mpg.de/index.php). Indeed, the
higher cost and turnaround time associated with triplicate
testing do not appear to be justified, at least in virologically
suppressed patients.
Recent guidelines suggest using an FPR of 10 % when
triplicate amplification is performed and an FPR of 20 %
for single amplification [1]. We thus compared tropism
prediction results obtained via single and triple amplifica-
tion using the FPRs reported by the guidelines. This ana-
lysis resulted in nine cases of discordant tropism
prediction, and in particular in eight reclassification from
CXCR4 to CCR5 tropism. This result suggests that the use
Table 3 Overview of reclassified samples using a triplicate tropism procedure
FPR ID FPR by single
amplification
FPR by triplicate amplification Tropism reclassification HIV-DNA
copies/10e-6 PBMCs
FPR A FPR B FPR C Singlicate Triplicate
5.75 % 13 11.4 4.7 2.8 3.7 R5 X4 1,303
80 34.3 1.5 1.5 58.7 R5 X4 425
96 6 5.8 1.7 37.1 R5 X4 Not available
95 5.7 13.2 13.2 13.2 X4 R5 372
10 % 13 11.4 4.7 2.8 3.7 R5 X4 1,303
80 34.3 1.5 1.5 58.7 R5 X4 425
20 19.4 17 7.8 36.4 R5 X4 1,768
95 5.7 13.2 13.2 13.2 X4 R5 372
20 % 80 34.3 1.5 1.5 58.7 R5 X4 425
Guidelines approacha 80 34.3 1.5 1.5 58.7 R5 X4 425
82 16.6 20.5 20.5 17.2 X4 R5 –
95 5.7 13.2 13.2 13.2 X4 R5 372
156 17.3 17.3 18.2 18.2 X4 R5 –
161 10.5 17 17 17 X4 R5 –
169 17 15.4 15.4 15.4 X4 R5 –
177 13.8 13.8 13.8 13.8 X4 R5 –
182 11.4 18 18 18 X4 R5 –
223 12 12 12 12 X4 R5 –
The table reports samples with a different tropism prediction using the single or the triplicate amplification procedure. The FPRs used as cut-off
for tropism prediction were: 5.75, 10, and 20 %, respectively. For the triple amplification, an isolate was predicted as CXCR4-tropic if at least
one of the three tests was reported to be CXCR4-tropic
a The European guidelines [1] advise a FPR of 10 % when triplicate amplification is used, and a FPR of 20 % for single amplification
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of an FPR of 20 % as a cutoff for tropism determination
can substantially reduce the number of patients assessed to
be candidates for treatment with the CCR5 antagonist.
We found that a FPR of \5.75 was associated not only
with a lower CD4 cell count at the time of V3 sequencing
but also with a lower increase in the CD4 cell count during
HAART despite virological success being achieved. These
results are in line with a previous study in viremic patients
showing that a FPR of B2 % defines a viral population
associated with a low CD4 rank, potentially greater cyto-
pathic effect, and more advanced disease [16]. Interest-
ingly, we also found an inverse correlation between FPR
and CD8 ? cell count. In particular, we found that a FPR
of \5.75 was associated with an higher CD8 cell count at
the time of V3 sequencing. This could be explained by the
proven interaction between CD8 ? T cell antiviral activity
and the rate of CD4 ? T-cell decline [17], and also by the
ability of CD8 ? T-lymphocytes to suppress CXCR4 HIV-
1 replication [18]. Thus, a finer use of genotypic tropism
testing might be useful to gain information regarding the
pathogenic potential of HIV.
In conclusion, we have developed a population-based
sequencing assay for genotypic HIV-1 tropism determina-
tion on HIV-DNA. Using this assay, it is possible to
examine both PBMC and whole blood samples from
patients with undetectable viral loads. The assay also
covers the spectrum of HIV-1 group M subtypes. The assay
is robust and can be set up easily in any standard clinical
laboratory. Our results support the feasibility and consis-
tency of genotypic tropism testing on HIV-DNA as a lab-
oratory tool, potentially assisting the selection of patients
with suppressed plasma HIV-1 RNA as candidates for
CCR5-antagonist treatment as part of switching, simplifi-
cation, or intensification strategies.
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Appendix 1
The complete list of centers and members participating in
the DIVA programme is as follows: ‘‘San Raffaele’’ Hos-
pital (Milan): Adriano Lazzarin, Massimo Clementi, Silvia
Nozza, Filippo Canducci, Enzo Boeri, Angela Rosa Pig-
nataro, Francesco Santoro; ‘‘L. Sacco’’ Hospital (Milan):
Giuliano Rizzardini, Massimo Galli, Valeria Micheli;
‘‘S. Paolo’’ Hospital (Milan): Antonella D’Arminio Monforte;
Busto Arsizio Hospital (Busto Arsizio [MI]): Tiziana
Quirino; ‘‘S. Gerardo’’ Hospital (Monza [MI]): Andrea
Gori, Laura Vecchi; Ospedali Riuniti (Bergamo): Franco
Maggiolo, Anna Paola Callegaro; IRCCS Policlinico
S. Matteo (Pavia): Renato Maserati, Fausto Baldanti, Stefania
Paolucci, Roberto Gulminetti; Ospedali Civili di Brescia:
Francesco Castelli, Franco Gargiulo; University of Turin
(Turin): Giovanni Di Perri, Valeria Ghisetti, Tiziano Al-
lice; University of Padova: Saverio Parisi, Renzo Scaggi-
ante; Policlinico ‘‘S. Orsola-Malpighi’’ (Bologna): Marco
Borderi, Maria Carla Re, Isabella Bon; ‘‘San Martino’’
Hosptial (Genova): Claudio Viscoli, Antonio Di Biagio,
Bianca Bruzzone, Renata Barresi, Silvia Calderisi; Poli-
clinico of Modena (Modena): Cristina Mussini, William
Gennari, Monica Pecorari; Marche Politechnic University
Medical School (Ancona): Andrea Giacometti, Alessia
Monachetti, Patrizia Bagnarelli; ‘‘S.M. Annunziata’’ Hos-
pital (Firenze): Francesco Mazzotta, Massimo Di Pietro;
‘‘Careggi’’ Hospital (Firenze): Francesco Leoncini, Gae-
tana Sterrantino, Canio Martinelli; AOUPisana: Maria
Linda Vatteroni; University of Siena (Siena): Maurizio
Zazzi, Andrea De Luca, Genni Meini; University of ‘‘Tor
Vergata’’ (Rome): Carlo Federico Perno, Valentina Svi-
cher, Claudia Alteri, Fabioloa Di Santo, Michela Pollicita,
Massimo Andreoni Gaetano Maffongelli, Marco Montano,
Alessandra Nori; IN.M.I. ‘‘L. Spallanzani’’ (Rome):
Andrea Antinori, Carlo Federico Perno, Roberta D’Arrigo,
Maria Rosaria Capobianchi; University of Rome ‘‘La
Sapienza’’ (Rome): Vincenzo Vullo, Guido Antonelli,
Ombretta Turriziani; Catholic University ‘‘Sacro Cuore’’
(Rome): Roberto Cauda, Emanuela Colafigli, Giovanni
Fadda, Rosaria Santangelo; Pescara General Hospital:
Giustino Parruti; Ospedale Cotugno: Antonio Chirianni,
Giuseppe Di Nicuolo; University of Foggia and Bari:
Gioacchino Angarano, Laura Monno, Annalisa Saracino,
Grazia Punzi.
Appendix 2
The cellular line 8E5, containing one copy of HIV-1 DNA
integrated for each cell, was used to build a standard curve
of seven dilutions (75,000–37,500–3,750–375–37.5–3.75–
1.87 copies). The sensitivity of PCR is one copy of HIV-1
DNA per reaction (one copy per reaction = 3.3 copies/106
PBMCs). The HIV-1 DNA target was hybridized with the
TaqMan probe and read on channel F1/F2 of the Light-
Cycler system (Roche Molecular Systems, Indianapolis,
IN). To verify DNA integrity, the reagents of the LC
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Control DNA kit (Roche) were used, amplifying a 110-bp
fragment of human b-globin in the same reaction. This
second internal control target was hybridized with the
FRET probe and read on channel F3/F2 of the LightCycler
system. To verify the accuracy of the Real Time PCR
results, different HIV-1 DNA standards (AIDS Research
and Reference Reagent Program, DAIDS, NIAID, NIH:
PCR Panel 001 from Dr. Shirley Kwok and Dr. Cindy
Christopherson, Roche Molecular Systems) were also
quantified. The quantification of total HIV-1 DNA was
centralized and performed at the laboratories of the Uni-
versity of Tor Vergata. Each center participating to the
DIVA project kept the samples at -70 C (or at -20 C if
not available) for up to 4 weeks. Samples were then sent to
the University of Tor Vergata in dry ice.
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